21719-25-5

Upstream product

• 99-81-0 4-Nitrophenacyl bromide 
• 555-16-8 4-nitrobenzaldehdye 
• 16428-47-0 2-Hydroxy-2-(4-nitrophenyl)ethylamine 
• 98-59-9 p-toluenesulfonyl chloride 
• 18731-47-0 1-(4-nitrophenyl)-2-nitroethanol 

Downstream Products

• 1393901-42-2 2-(4-nitrophenyl)-4-tosylmorpholine 
• 1393900-60-1 2-(2-(2-(2-((4-(morpholin-2-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)ethyl)phenyl)acetamide 
• 1393901-45-5 tert-butyl 2-(4-((4-(2-(2-amino-2-oxoethyl)phenethyl)-5-(trifluoromethyl)pyrimidin-2-yl)amino)phenyl)morpholine-4-carboxylate 
• 1393901-44-4 2-(2-(2-(2-((4-(4-(tert-butoxycarbonyl)morpholin-2-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)ethyl)phenyl)acetic acid 
• 1393901-43-3 tert-butyl 2-(4-((4-(2-(2-methoxy-2-oxoethyl)phenethyl)-5-(trifluoromethyl)pyrimidin-2-yl)amino)phenyl)morpholine-4-carboxylate 
• 1286738-75-7 2-(4-nitrophenyl)morpholine-4-carboxylic acid tert-butyl ester 
• 1002726-96-6 2-(4-aminophenyl)morpholine-4-carboxylic acid tert-butyl ester 
• 61192-65-2 2-(4-nitrophenyl)morpholine 

Relevant academic research and scientific papers

Lewis acid mediated intramolecular C-O bond formation of alkanol-epoxide leading to substituted morpholine and 1,4-oxazepane derivatives: Total synthesis of (±)-Viloxazine

Substituted morpholines have been efficiently synthesised in good yields from nitrogen tethered alkanol-epoxide mediated by boron trifluoride etherate. The methodology has been used for the total synthesis of (±)-viloxazine.

FAK AND FLT3 INHIBITORS

The use of a compound of the formula (I): (Formula (I)) in the preparation of a medicament for treating Acute Myeloid Leukemia or a disease ameliorated by the inhibition of Flt3, or Flt3 and FAK.

FAK INHIBITORS

A compound of the formula (I): where R1 or R2 is a cycle amine group and R5 is an aromatic group with a carbonyl containing substituent for use as a FAK inhibitor.